KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Assets (2016 - 2025)

Novavax (NVAX) has 16 years of Current Assets data on record, last reported at $974.6 million in Q3 2025.

  • For Q3 2025, Current Assets fell 11.7% year-over-year to $974.6 million; the TTM value through Sep 2025 reached $974.6 million, down 11.7%, while the annual FY2024 figure was $1.1 billion, 1.31% down from the prior year.
  • Current Assets reached $974.6 million in Q3 2025 per NVAX's latest filing, up from $919.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $2.4 billion in Q2 2021 and bottomed at $727.1 million in Q1 2024.
  • Average Current Assets over 5 years is $1.5 billion, with a median of $1.1 billion recorded in 2023.
  • Peak YoY movement for Current Assets: soared 780.29% in 2021, then crashed 58.63% in 2023.
  • A 5-year view of Current Assets shows it stood at $2.2 billion in 2021, then decreased by 20.96% to $1.7 billion in 2022, then tumbled by 32.85% to $1.1 billion in 2023, then dropped by 1.31% to $1.1 billion in 2024, then decreased by 13.67% to $974.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $974.6 million in Q3 2025, $919.5 million in Q2 2025, and $868.0 million in Q1 2025.